An on-going phase I/II trial using zenocutuzumab (HER2/HER3 inhibitor), has already enrolled 250 pancreatic cancer patients harbouring neuregulin-1 (NRG1) gene fusion (NCT02912949). Here, NRG1 is linked to familial pancreatic carcinoma.